Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02069730
Other study ID # GEMS-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 2014
Est. completion date December 2027

Study information

Verified date January 2024
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study of select drug therapies in patients with salivary gland cancer. The study has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2). Based on the Molecular profiling results in phase the participants will receive matched treatment if a specific aberration is identified or will receive treatment with Selinexor if unmatched and no druggable aberration is identified.


Description:

In molecular profiling phase of the study, participants will provide a sample of their tumor tissue to test for changes in certain genes that show whether certain drug treatments will be more useful than others. Once participants have undergone molecular profiling, they will be offered a drug treatment depending on the results. Certain drug treatments are designed to target certain gene changes. If there is a matching drug treatment, participants will be offered that treatment (either outside a clinical trial or within a clinical trial). If there are no gene changes or there are changes to genes were there are no drug treatments available for those certain changes, participants will be offered the study drug, Selinexor. Cancer is the uncontrolled growth of cells. Research shows that one way cancer cells can grow uncontrollably is when certain proteins, called exporter proteins, are present in high levels in the body. These proteins prevent certain other proteins important in protecting cells from becoming cancerous and important in the controlling the growth of cells, from working. The study drug Selinexor is new class of drug called Selective Inhibitor of Nuclear Export (SINE) that blocks the exporter proteins from working which may allow the other proteins to work and slow or stop tumors from growing.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 114
Est. completion date December 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (Phase 1, Molecular Profiling): - Have available archival tumor tissue or fresh tumor specimen from diagnostic histological tissue for molecular profiling. - Histological or cytological proof of malignant salivary gland tumor - ECOG performance score 0-2 - Documented evidence of recurrent or metastatic disease Inclusion Criteria (Phase 2, Treatment): - Interpretable result of molecular profiling in the molecular profiling phase of this study - Advanced recurrent or metastatic salivary gland cancer for which no curative therapy exists - Evidence of clinical or radiological disease progression at the time of study treatment - At least one measurable target lesion as defined by RECIST 1.1 - Must have adequate hematological, liver, renal and cardiac function - No concomitant use of drugs which may prolong QTc interval - No history of serious cardiac illness - No serious medical conditions that might be aggravated by treatment or limit compliance. - Central nervous system metastases are permitted provided these are clinically stable - Able to take oral medication and have no evidence of bowel obstruction, infectious/inflammatory bowel disease - No other active malignancy at any other site - 18 years of age or older - Measureable disease as defined by RECIST v1.1 - Not receiving any other concurrent investigational agent - If the matched treatment is in the context of another phase I trial, the eligibility criteria of the enrolled trial will be used instead of the criteria from this trial Exclusion Criteria (Phase 1, Molecular Profiling): - Refuses to have tumor tissue undergo molecular profiling - Not enough tumor tissue for molecular profiling - Life expectancy less than 3 months Exclusion Criteria (Phase 2, Treatment): - Had stopped the previous treatment but showed no clinical or radiological evidence of disease progression - Have received the same drug treatment of assignment to the specific arm before the enrolment in to treatment phase (phase 2)

Study Design


Intervention

Drug:
Selinexor
If no "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE).
EGFR or HER2 Inhibitor
If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor
FGFR Inhibitor
If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor
C-KIT Inhibitor
If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor
Anti-androgen
If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens
NOTCH Inhibitor
If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor
MEK or PI3K Inhibitor
If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor

Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with complete and partial response to unmatched therapy Selinexor compared to matched therapies Overall Response rate in the setting of matched and unmatched therapy. 4 years
Secondary Number of participants with complete, partial and/or stable disease to unmatched therapy Selinexor compared to matched therapies Disease control Rate in the setting of matched and unmatched therapy. 4 years
Secondary Length of time that participant's disease does not worsen Progression free survival rate in the setting of matched and unmatched therapy. 6 months
Secondary Percentage of each molecular aberrations in metastatic salivary gland tumors Molecular profiling results in malignant salivary gland tumor 4 years
See also
  Status Clinical Trial Phase
Terminated NCT03729297 - Cabozantinib in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT01969578 - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Phase 2
Completed NCT01703455 - Activity of Sorafenib in Salivary Gland Cancer Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Active, not recruiting NCT03781986 - APG-115 in Salivary Gland Cancer Trial Phase 1/Phase 2
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05483374 - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT03172624 - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Phase 2
Completed NCT00509002 - Iressa Study in Patients With Salivary Gland Cancer Phase 2
Active, not recruiting NCT05008237 - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study Phase 2
Recruiting NCT03360890 - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Phase 2
Not yet recruiting NCT05898373 - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC Phase 1/Phase 2
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Completed NCT01344356 - Stereotactic Body Radiotherapy for Head and Neck Tumors Phase 4
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Not yet recruiting NCT06091878 - Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers